Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
JCI Insight · 23.02.2026 · 11 (4)
DOI: 10.1172/jci.insight.192113 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 15.01.2026. Verfasst von Mehri Monavarian und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birm…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Anoikis, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase 8. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Cellular Pathology, Department of Pathology, O'Neal Cancer Center, Heersink School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
- UAB Biological Data Science Core, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona, USA.
- Department of Bioengineering, Indian Institute of Science, Bangalore, India.
- Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Neurobiology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Monavarian, M., Rajkarnikar, R., Page, E. F., Kumari, A., Quintero Macias, L., Massicano, F., Lee, N. Y., Sahoo, S., Hempel, N., Jolly, M. K., Ianov, L., Worthey, E., Singh, A., Roninson, I. B., Broude, E. V., Chen, M., & Mythreye, K. (2026). Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition. JCI Insight, 11(4). https://doi.org/10.1172/jci.insight.192113
Vancouver
Monavarian M, Rajkarnikar R, Page EF, Kumari A, Quintero Macias L, Massicano F, et al. Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition. JCI Insight. 2026;11(4). doi:10.1172/jci.insight.192113
BibTeX
@article{Monavarian2026,
author = {Monavarian, Mehri and Rajkarnikar, Resha and Page, Emily Faith and Kumari, Asha and Quintero Macias, Liz and Massicano, Felipe and Lee, Nam Y and Sahoo, Sarthak and Hempel, Nadine and Jolly, Mohit Kumar and Ianov, Lara and Worthey, Elizabeth and Singh, Abhyudai and Roninson, Igor B and Broude, Eugenia V and Chen, Mengqian and Mythreye, Karthikeyan},
title = {Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {4},
doi = {10.1172/jci.insight.192113}
}
EUVIMED